TMCnet News
resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition and Neurodegenerative DiseaseBOSTON, Jan. 31, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced it will host a key opinion leader (KOL) symposium on the potential of TORC1 inhibition to ameliorate neurodegenerative disease, with a focus on Parkinson’s disease, on Thursday, February 7, 2019 at 8:30 a.m. ET in New York, NY. Guest speakers scheduled to present at the event include:
Additionally, resTORbio management will provide an overview of the Company’s recent progress, icluding the clinical program planned for its selective TORC1 inhibitor, RTB101, in Parkinson’s disease. A live audio webcast of the event can be accessed on the resTORbio website, www.restorbio.com. An archived replay will be available for at least 30 days after the event concludes. About resTORbio Investor Contact Media Contact |